The changing landscape in metastatic castration-resistant prostate cancer.
about
Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer.Genetic interaction of P2X7 receptor and VEGFR-2 polymorphisms identifies a favorable prognostic profile in prostate cancer patients.Osteopontin splice variants expression is involved on docetaxel resistance in PC3 prostate cancer cells.
P2860
The changing landscape in metastatic castration-resistant prostate cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
The changing landscape in metastatic castration-resistant prostate cancer.
@en
type
label
The changing landscape in metastatic castration-resistant prostate cancer.
@en
prefLabel
The changing landscape in metastatic castration-resistant prostate cancer.
@en
P1476
The changing landscape in metastatic castration-resistant prostate cancer.
@en
P2093
Raya Leibowitz-Amit
P304
P356
10.1097/SPC.0B013E328362FFEF
P577
2013-09-01T00:00:00Z